FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377010952> ?p ?o ?g. }

• W4377010952 endingPage "46" @default.
• W4377010952 startingPage "35" @default.
• W4377010952 abstract "Background: Pulsed field ablation is a novel nonthermal cardiac ablation modality using ultra-rapid electrical pulses to cause cell death by a mechanism of irreversible electroporation. Unlike the traditional ablation energy sources, pulsed field ablation has demonstrated significant preferentiality to myocardial tissue ablation, and thus avoids certain thermally mediated complications. However, its safety and effectiveness remain unknown in usual clinical care. Methods: MANIFEST-PF (Multi-National Survey on the Methods, Efficacy, and Safety on the Post-Approval Clinical Use of Pulsed Field Ablation) is a retrospective, multinational, patient-level registry wherein patients at each center were prospectively included in their respective center registries. The registry included all patients undergoing postapproval treatment with a multielectrode 5-spline pulsed field ablation catheter to treat atrial fibrillation (AF) between March 1, 2021, and May 30, 2022. The primary effectiveness outcome was freedom from clinical documented atrial arrhythmia (AF/atrial flutter/atrial tachycardia) of ≥30 seconds on the basis of electrocardiographic data after a 3-month blanking period (on or off antiarrhythmic drugs). Safety outcomes included the composite of acute (<7 days postprocedure) and latent (>7 days) major adverse events. Results: At 24 European centers (77 operators) pulsed field ablation was performed in 1568 patients with AF: age 64.5±11.5 years, female 35%, paroxysmal/persistent AF 65%/32%, CHA 2 DS 2 -VASc 2.2±1.6, median left ventricular ejection fraction 60%, and left atrial diameter 42 mm. Pulmonary vein isolation was achieved in 99.2% of patients. After a median (interquartile range) follow-up of 367 (289–421) days, the 1-year Kaplan-Meier estimate for freedom from atrial arrhythmia was 78.1% (95% CI, 76.0%–80.0%); clinical effectiveness was more common in patients with paroxysmal AF versus persistent AF (81.6% versus 71.5%; P =0.001). Acute major adverse events occurred in 1.9% of patients. Conclusions: In this large observational registry of the postapproval clinical use of pulsed field technology to treat AF, catheter ablation using pulsed field energy was clinically effective in 78% of patients with AF." @default.
• W4377010952 created "2023-05-19" @default.
• W4377010952 creator A5001858112 @default.
• W4377010952 creator A5005827563 @default.
• W4377010952 creator A5010477994 @default.
• W4377010952 creator A5012287531 @default.
• W4377010952 creator A5012582339 @default.
• W4377010952 creator A5014632668 @default.
• W4377010952 creator A5018792893 @default.
• W4377010952 creator A5019535008 @default.
• W4377010952 creator A5019788286 @default.
• W4377010952 creator A5022853867 @default.
• W4377010952 creator A5023180490 @default.
• W4377010952 creator A5026895339 @default.
• W4377010952 creator A5028570685 @default.
• W4377010952 creator A5028706323 @default.
• W4377010952 creator A5032860919 @default.
• W4377010952 creator A5033287078 @default.
• W4377010952 creator A5035830496 @default.
• W4377010952 creator A5035949904 @default.
• W4377010952 creator A5037739178 @default.
• W4377010952 creator A5037741543 @default.
• W4377010952 creator A5039520035 @default.
• W4377010952 creator A5040713582 @default.
• W4377010952 creator A5040798271 @default.
• W4377010952 creator A5042270657 @default.
• W4377010952 creator A5043036813 @default.
• W4377010952 creator A5044072524 @default.
• W4377010952 creator A5049795837 @default.
• W4377010952 creator A5051852661 @default.
• W4377010952 creator A5052838808 @default.
• W4377010952 creator A5053215060 @default.
• W4377010952 creator A5053571962 @default.
• W4377010952 creator A5054480372 @default.
• W4377010952 creator A5055509099 @default.
• W4377010952 creator A5058680940 @default.
• W4377010952 creator A5062899530 @default.
• W4377010952 creator A5063097243 @default.
• W4377010952 creator A5065968361 @default.
• W4377010952 creator A5066939323 @default.
• W4377010952 creator A5072159318 @default.
• W4377010952 creator A5072579408 @default.
• W4377010952 creator A5073033425 @default.
• W4377010952 creator A5074774006 @default.
• W4377010952 creator A5077829759 @default.
• W4377010952 creator A5078690704 @default.
• W4377010952 creator A5080007807 @default.
• W4377010952 creator A5086144947 @default.
• W4377010952 creator A5087577051 @default.
• W4377010952 creator A5088850609 @default.
• W4377010952 creator A5090502339 @default.
• W4377010952 creator A5091734035 @default.
• W4377010952 creator A5091866817 @default.
• W4377010952 date "2023-07-04" @default.
• W4377010952 modified "2023-10-14" @default.
• W4377010952 title "Safety and Effectiveness of Pulsed Field Ablation to Treat Atrial Fibrillation: One-Year Outcomes From the MANIFEST-PF Registry" @default.
• W4377010952 cites W1854913079 @default.
• W4377010952 cites W1976519635 @default.
• W4377010952 cites W1992956108 @default.
• W4377010952 cites W2005707796 @default.
• W4377010952 cites W2087825738 @default.
• W4377010952 cites W2116263229 @default.
• W4377010952 cites W2612100421 @default.
• W4377010952 cites W2613153832 @default.
• W4377010952 cites W2615954481 @default.
• W4377010952 cites W2802955859 @default.
• W4377010952 cites W2898798478 @default.
• W4377010952 cites W2917550741 @default.
• W4377010952 cites W2944063628 @default.
• W4377010952 cites W2996628889 @default.
• W4377010952 cites W3002587012 @default.
• W4377010952 cites W3021035433 @default.
• W4377010952 cites W3021352261 @default.
• W4377010952 cites W3045423783 @default.
• W4377010952 cites W3080498817 @default.
• W4377010952 cites W3082188176 @default.
• W4377010952 cites W3116299162 @default.
• W4377010952 cites W3141316515 @default.
• W4377010952 cites W3157144004 @default.
• W4377010952 cites W3157697661 @default.
• W4377010952 cites W3204424978 @default.
• W4377010952 cites W4206136321 @default.
• W4377010952 cites W4226412814 @default.
• W4377010952 cites W4282007469 @default.
• W4377010952 cites W4297891405 @default.
• W4377010952 cites W4319068181 @default.
• W4377010952 cites W4319461161 @default.
• W4377010952 cites W4323294621 @default.
• W4377010952 doi "https://doi.org/10.1161/circulationaha.123.064959" @default.
• W4377010952 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37199171" @default.
• W4377010952 hasPublicationYear "2023" @default.
• W4377010952 type Work @default.
• W4377010952 citedByCount "12" @default.
• W4377010952 countsByYear W43770109522023 @default.
• W4377010952 crossrefType "journal-article" @default.
• W4377010952 hasAuthorship W4377010952A5001858112 @default.
• W4377010952 hasAuthorship W4377010952A5005827563 @default.
• W4377010952 hasAuthorship W4377010952A5010477994 @default.

• next